Index RUT
P/E -
EPS (ttm) -1.56
Insider Own 23.96%
Shs Outstand 84.88M
Perf Week 2.67%
Market Cap 519.49M
Forward P/E -
EPS next Y -1.50
Insider Trans -0.37%
Shs Float 73.29M
Perf Month -6.42%
Income -130.39M
PEG -
EPS next Q -0.51
Inst Own 65.04%
Short Float 9.41%
Perf Quarter -7.55%
Sales 97.06M
P/S 5.35
EPS this Y -34.79%
Inst Trans 0.70%
Short Ratio 10.70
Perf Half Y -1.28%
Book/sh 1.58
P/B 3.41
EPS next Y 28.54%
ROA -18.50%
Short Interest 6.90M
Perf Year -17.84%
Cash/sh 5.69
P/C 0.95
EPS next 5Y -10.70%
ROE -74.81%
52W Range 3.66 - 9.06
Perf YTD -32.46%
Dividend Est. -
P/FCF -
EPS past 5Y -15.76%
ROI -79.21%
52W High -40.54%
Beta 0.78
Dividend TTM -
Quick Ratio 3.18
Sales past 5Y 158.96%
Gross Margin 90.88%
52W Low 47.27%
ATR (14) 0.33
Dividend Ex-Date -
Current Ratio 3.18
EPS Y/Y TTM 3.67%
Oper. Margin -156.33%
RSI (14) 47.11
Volatility 6.81% 5.84%
Employees 244
Debt/Eq 0.29
Sales Y/Y TTM -27.36%
Profit Margin -134.34%
Recom 1.90
Target Price 14.43
Option/Short Yes / Yes
LT Debt/Eq 0.23
EPS Q/Q 22.49%
Payout -
Rel Volume 0.48
Prev Close 5.34
Sales Surprise 71.89%
EPS Surprise 36.45%
Sales Q/Q 5.19%
Earnings Feb 27 AMC
Avg Volume 644.55K
Price 5.39
SMA20 -0.90%
SMA50 -9.95%
SMA200 -13.27%
Trades
Volume 306,288
Change 0.94%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Upgrade
Stifel
Hold → Buy
$8 → $15
Dec-12-23 Initiated
Deutsche Bank
Buy
$12
Sep-25-23 Initiated
Goldman
Sell
$4
Sep-22-23 Initiated
Cantor Fitzgerald
Overweight
$13
Jan-06-23 Downgrade
BofA Securities
Buy → Neutral
$24 → $12
Sep-09-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$27 → $13
Jul-07-22 Initiated
Mizuho
Buy
$15
Apr-13-22 Initiated
Goldman
Sell
$9
Mar-08-22 Downgrade
Stifel
Buy → Hold
$32 → $18
Sep-27-21 Initiated
William Blair
Outperform
Jan-15-21 Resumed
BofA Securities
Buy
$35
Jun-24-20 Initiated
H.C. Wainwright
Buy
$41
Apr-28-20 Initiated
Goldman
Buy
$32
Mar-06-20 Initiated
Citigroup
Buy
$40
Feb-27-20 Initiated
Barclays
Overweight
$36
Feb-19-20 Initiated
Stifel
Buy
$44
Nov-21-19 Initiated
BTIG Research
Buy
$28
Mar-04-19 Initiated
SVB Leerink
Outperform
Mar-04-19 Initiated
Morgan Stanley
Overweight
$27
Mar-04-19 Initiated
BofA/Merrill
Buy
$26
Show Previous Ratings
Apr-25-24 10:02AM
Feb-28-24 02:02PM
(Thomson Reuters StreetEvents)
10:13AM
07:00AM
Feb-27-24 04:46PM
04:23PM
Loading…
04:23PM
(Associated Press Finance)
04:05PM
Feb-20-24 04:05PM
10:00AM
Feb-08-24 07:00AM
06:48AM
Feb-07-24 07:00AM
Jan-25-24 12:00PM
Jan-23-24 07:32AM
Jan-19-24 09:20AM
08:54AM
Loading…
Jan-17-24 08:54AM
Jan-16-24 04:01PM
Jan-08-24 01:25PM
(Investor's Business Daily) +7.34%
Dec-05-23 09:55AM
Nov-28-23 07:00AM
Nov-14-23 09:35AM
Nov-08-23 07:00AM
Nov-07-23 06:02PM
(Associated Press Finance) +5.12%
05:11PM
04:05PM
Oct-27-23 07:00AM
Sep-14-23 01:12AM
Sep-08-23 12:10PM
Sep-07-23 07:00AM
Aug-31-23 07:00AM
09:55AM
Loading…
Aug-10-23 09:55AM
Aug-03-23 05:45PM
04:43PM
(Associated Press Finance)
04:05PM
Jul-27-23 08:30AM
Jul-13-23 01:29PM
Jun-06-23 07:00AM
Jun-01-23 07:29AM
May-09-23 09:55AM
May-05-23 06:31AM
(Simply Wall St.) +10.27%
May-04-23 07:35PM
06:27PM
04:05PM
May-02-23 07:00AM
May-01-23 10:01AM
Apr-27-23 10:03AM
Apr-13-23 12:59PM
08:30AM
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-20-23 10:00AM
Feb-17-23 06:01AM
Feb-16-23 10:01AM
Dec-21-22 05:01AM
Dec-08-22 04:30PM
Nov-29-22 11:05AM
Nov-10-22 05:13AM
(Simply Wall St.) +19.62%
Nov-08-22 07:45PM
04:05PM
Nov-07-22 07:00AM
Nov-04-22 11:05AM
Nov-03-22 04:30PM
Oct-13-22 08:00AM
Oct-06-22 04:30PM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-09-22 09:55AM
Aug-06-22 08:33AM
Aug-04-22 07:15PM
04:05PM
Jul-08-22 10:54AM
Jul-07-22 05:59PM
(American City Business Journals)
Jun-08-22 07:00AM
May-28-22 08:20AM
May-27-22 04:30PM
May-05-22 06:25PM
04:05PM
May-04-22 07:00AM
May-02-22 07:47AM
Apr-27-22 03:03PM
Mar-29-22 04:05PM
Mar-15-22 12:04PM
08:00AM
Mar-09-22 07:00AM
Mar-08-22 07:00AM
Mar-01-22 04:30PM
04:05PM
Feb-24-22 06:50PM
04:05PM
Feb-17-22 03:02PM
Feb-14-22 04:30AM
Feb-07-22 08:30AM
Feb-01-22 11:13AM
Jan-11-22 01:30AM
01:30AM
Jan-10-22 11:07AM
(American City Business Journals)
Jan-03-22 04:30PM
Jan-02-22 06:32AM
Dec-24-21 12:38AM
Dec-16-21 11:03AM
(American City Business Journals)
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rosenthal Arnon Chief Executive Officer Mar 04 '24 Sale 6.92 18,837 130,386 2,000,380 Mar 05 06:00 PM Kenkare-Mitra Sara President and Head of R&D Mar 04 '24 Sale 6.92 10,169 70,387 318,847 Mar 05 06:00 PM Romano Gary Chief Medical Officer Mar 04 '24 Sale 6.92 6,001 41,554 196,313 Mar 05 06:00 PM GRASSO MARC Chief Financial Officer Mar 04 '24 Sale 6.92 5,716 39,562 144,957 Mar 05 06:00 PM Rosenthal Arnon Chief Executive Officer Dec 04 '23 Sale 5.56 23,831 132,500 2,019,217 Dec 06 06:30 PM Kenkare-Mitra Sara President and Head of R&D Dec 04 '23 Sale 5.56 12,519 69,606 329,016 Dec 06 06:30 PM Romano Gary Chief Medical Officer Dec 04 '23 Sale 5.56 5,035 27,995 202,314 Dec 06 06:30 PM GRASSO MARC Chief Financial Officer Dec 04 '23 Sale 5.56 4,574 25,431 150,673 Dec 06 06:30 PM Polaris Venture Management Co. 10% Owner Sep 11 '23 Sale 6.00 500,000 3,000,000 10,853,817 Sep 13 04:33 PM MCGUIRE TERRANCE Director Sep 11 '23 Sale 6.00 500,000 3,000,000 10,853,817 Sep 13 04:29 PM Kenkare-Mitra Sara President and Head of R&D Sep 05 '23 Sale 5.19 6,214 32,277 177,935 Sep 06 07:17 PM Rosenthal Arnon Chief Executive Officer Sep 05 '23 Sale 5.19 5,647 29,333 1,645,448 Sep 06 07:18 PM Romano Gary Chief Medical Officer Sep 05 '23 Sale 5.19 2,771 14,393 99,349 Sep 06 07:16 PM GRASSO MARC Chief Financial Officer Sep 05 '23 Sale 5.19 1,114 5,786 32,247 Sep 06 07:14 PM Rosenthal Arnon Chief Executive Officer Jun 02 '23 Sale 6.90 5,255 36,279 1,651,095 Jun 05 06:48 PM Kenkare-Mitra Sara President and Head of R&D Jun 02 '23 Sale 6.90 4,092 28,250 184,149 Jun 05 06:54 PM Romano Gary Chief Medical Officer Jun 02 '23 Sale 6.90 2,617 18,067 102,120 Jun 05 06:50 PM GRASSO MARC Chief Financial Officer Jun 02 '23 Sale 6.90 1,050 7,249 33,361 Jun 05 06:52 PM
Index -
P/E -
EPS (ttm) -9.07
Insider Own 27.57%
Shs Outstand 2.47M
Perf Week 0.85%
Market Cap 8.01M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 1.96M
Perf Month -3.75%
Income -21.02M
PEG -
EPS next Q -
Inst Own 39.47%
Short Float 1.03%
Perf Quarter 1.98%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans 20.21%
Short Ratio 6.74
Perf Half Y -8.80%
Book/sh 4.56
P/B 0.65
EPS next Y -
ROA -119.14%
Short Interest 0.02M
Perf Year -53.83%
Cash/sh 2.79
P/C 1.06
EPS next 5Y -
ROE -172.37%
52W Range 1.75 - 6.75
Perf YTD -11.79%
Dividend Est. -
P/FCF -
EPS past 5Y 36.06%
ROI -186.17%
52W High -56.22%
Beta 1.87
Dividend TTM -
Quick Ratio 3.85
Sales past 5Y -33.97%
Gross Margin -
52W Low 68.85%
ATR (14) 0.31
Dividend Ex-Date -
Current Ratio 3.85
EPS Y/Y TTM 55.26%
Oper. Margin 0.00%
RSI (14) 47.48
Volatility 6.82% 7.76%
Employees 1
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 80.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 79.35%
Payout -
Rel Volume 0.56
Prev Close 2.82
Sales Surprise -13.92%
EPS Surprise -3.33%
Sales Q/Q -100.00%
Earnings -
Avg Volume 2.99K
Price 2.95
SMA20 -5.22%
SMA50 -4.24%
SMA200 -8.15%
Trades
Volume 1,680
Change 4.79%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-20-21 Initiated
Truist
Buy
$14
Sep-24-21 Initiated
Cantor Fitzgerald
Overweight
$7
Jun-03-19 Initiated
Credit Suisse
Neutral
Apr-05-24 06:53AM
Mar-24-24 03:54PM
Dec-04-23 08:00AM
Nov-30-23 06:16PM
Aug-02-23 08:39PM
(American City Business Journals)
07:00AM
Loading…
Jul-31-23 07:00AM
Jun-01-23 04:00PM
May-15-23 01:00PM
May-12-23 02:59PM
May-11-23 06:00PM
06:00PM
Apr-03-23 07:30AM
Mar-27-23 07:00AM
Mar-22-23 04:40PM
Nov-22-22 07:00AM
06:34AM
Loading…
Nov-09-22 06:34AM
Oct-07-22 02:31PM
(American City Business Journals) -9.66%
Oct-06-22 12:46PM
08:00AM
Aug-09-22 05:35PM
04:00PM
Aug-08-22 09:22AM
(Simply Wall St.) +27.76%
Jul-28-22 07:00AM
Jul-26-22 07:00AM
Jun-28-22 09:00AM
Jun-22-22 08:30AM
Jun-17-22 11:20AM
08:00AM
Jun-10-22 07:00AM
Jun-06-22 07:00AM
09:30AM
Loading…
May-11-22 09:30AM
May-04-22 04:01PM
Feb-27-22 06:39AM
Feb-24-22 04:01PM
Feb-23-22 08:00AM
Feb-01-22 05:30AM
Jan-26-22 08:00AM
Dec-15-21 10:00AM
Nov-25-21 04:47AM
Nov-11-21 05:32PM
Nov-09-21 04:01PM
Nov-08-21 12:00PM
(American City Business Journals)
Oct-20-21 04:24PM
Oct-11-21 03:34AM
Oct-10-21 09:37AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-26-21 07:19AM
Aug-23-21 05:00PM
Jul-29-21 05:00PM
Jul-22-21 04:30PM
Jul-12-21 02:24AM
Jul-09-21 06:14AM
Jul-08-21 07:22PM
04:30PM
Jun-04-21 10:27AM
08:00AM
08:00AM
May-27-21 04:30PM
May-25-21 07:00AM
May-09-21 03:36AM
Apr-27-21 09:00AM
Apr-26-21 07:00AM
Apr-21-21 07:30AM
Apr-20-21 07:00AM
Mar-24-21 04:05PM
Mar-22-21 02:23AM
Mar-19-21 07:46AM
Mar-18-21 05:00PM
Feb-25-21 07:00AM
Jan-25-21 07:00AM
Jan-21-21 12:52AM
Jan-04-21 07:00AM
Dec-21-20 07:30AM
Dec-02-20 11:27PM
Nov-15-20 07:55AM
Nov-05-20 07:00AM
Oct-14-20 01:09PM
10:07AM
07:00AM
07:00AM
Oct-04-20 09:52AM
Sep-04-20 07:00AM
Aug-25-20 07:00AM
Aug-20-20 11:01AM
Aug-03-20 09:25AM
Jul-30-20 09:00AM
Jul-17-20 07:00AM
Jul-06-20 03:17PM
Jul-05-20 02:45PM
Jun-18-20 04:01PM
May-22-20 07:52AM
Apr-10-20 07:00AM
Mar-23-20 06:50AM
(Simply Wall St.) +18.94%
Jan-13-20 07:00AM
Jan-12-20 05:05PM
Dec-24-19 08:17AM
Dec-23-19 07:00AM
Dec-12-19 03:43PM
Nov-27-19 07:00AM
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCGUIRE TERRANCE Director Aug 09 '23 Sale 3.40 8 27 0 Aug 11 04:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite